Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.65M | -7.06M | -8.46M | -6.40M | -4.34M |
| Total Depreciation and Amortization | 143.80K | 135.40K | 127.00K | 93.90K | 60.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 756.80K | 1.47M | 2.19M | 1.42M | 641.80K |
| Change in Net Operating Assets | 458.20K | 243.30K | 28.40K | 230.90K | 433.40K |
| Cash from Operations | -4.29M | -5.20M | -6.11M | -4.66M | -3.20M |
| Capital Expenditure | -103.00K | -103.00K | -103.00K | -51.50K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 100.00 | 200.00 | 200.00 | 200.00 |
| Other Investing Activities | -13.20K | -12.70K | -12.20K | -5.80K | 600.00 |
| Cash from Investing | -116.40K | -115.90K | -115.40K | -57.40K | 600.00 |
| Total Debt Issued | 438.40K | 219.20K | -- | -- | -- |
| Total Debt Repaid | -128.00K | -132.90K | -137.80K | -105.40K | -73.00K |
| Issuance of Common Stock | 4.73M | 6.05M | 7.37M | 5.01M | 2.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -680.40K | -704.90K | -729.40K | -392.90K | -56.40K |
| Cash from Financing | 4.36M | 5.43M | 6.51M | 4.51M | 2.51M |
| Foreign Exchange rate Adjustments | -24.40K | -17.90K | -11.40K | 4.40K | 20.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.20K | 94.40K | 265.00K | -201.60K | -668.20K |